🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Karin Havenith

ORCID: 0000-0002-0610-4228

MedicineChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia”.

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Blood Advances(2020)10.1182/bloodadvances.2019000767

N/A

2.9DataRank · unranked

56 citations

Wendy Stock, Amer M. Zeidan, Ehab Atallah, James McCloskey, Leonard T. Heffner +11 more

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

The Lancet Haematology(2021)10.1016/s2352-3026(21)00103-4

N/A

2.5DataRank · unranked

86 citations

Graham P. Collins, Paolo F. Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies +13 more

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.06.570390

N/A

0DataRank · unranked

5 citations

Alexander B. Radaoui, Matthew Tsang, Daniel Martínez, Simone Sidoli, Karina L. Conkrite +31 more

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

Cancer Cell(2024)10.1016/j.ccell.2024.10.003

N/A

0DataRank · unranked

18 citations

Alexander B. Radaoui, Matthew Tsang, Daniel Martínez, Karina L. Conkrite, Khushbu Patel +33 more